Click here for slides on this topic


DURATION

A series of clinical trials comparing extended-release exenatide, and injectable agent for the treatment of type 2 diabetes, with other antihyperglycemic agents. 


The following content matched the glossary term: DURATION

Fonseca commentary on ADVANCE, SOS, VADT

Top

Expert commentary from NDEI Education Council Member Vivian A. Fonseca, MD, on data from post-hoc analyses of ADVANCE, SOS, and VADT.

Clinical Insights in Diabetes Newsletter December 2012

Top

Clinical Insights® in Diabetes newsletter December 2012 

Once-weekly exenatide vs once-daily liraglutide in DURATION-6, HDL-C and microvascular risk in ADVANCE, statins and valvular calcification in VADT, bariatric surgery and cardiovascular events in obesity and type 2 diabetes in SOS. 

Exenatide once weekly versus liraglutide once daily in patients with type 2 diabetes (DURATION-6): a randomised, open-label study.

Top

Buse JB, Nauck M, Forst T, et al. Exenatide once weekly versus liraglutide once daily in patients with type 2 diabetes (DURATION-6): a randomised, open-label study. Lancet. 2013;381(9861):117-124. DURATION (Diabetes Therapy Utilization: Researching Changes in A1C, Weight, and Other Factors Through Intervention with Exenatide Once-Weekly) is a series of multinational studies comparing once-weekly exenatide with other antihyperglycemic therapies for treatment of type 2 diabetes.



Slide Library Results

Search Results for: DURATION Slides Found: 140
Prevalence of Retinopathy in the San Luis Valley Diabetes Study
Prevalence of Retinopathy in the San Antonio Heart Study
Microvascular Complications in Hispanics and Non-Hispanic Whites
Retinopathy Complications in Patients With Type 2 Diabetes
Rates of End-Stage Renal Disease in Diabetes Four Ethnic Groups
Nontraumatic Lower Extremity Amputation and Type 2 Diabetes
Incidence of Type 2 Diabetes-Related Vascular Disease in Four Ethnic Groups
Behavior Therapy: Self-Monitoring
Behavior Therapy: Evolution of Results
Successful Weight Loss Maintenance: National Weight Control Registry
Effect of Early Thiazolidinedione Therapy on A1C Levels
Effect of Early Thiazolidinedione Therapy on C-Peptide Levels
Effect of Early Thiazolidinedione Therapy on Diabetes Onset
Gender Differences Influence Impact of Type 2 Diabetes on CHD Risk
Sustained Reduction in A1C During 1-Yr Treatment With Vildagliptin in Patients With T2D
Vildagliptin Is as Effective as Rosiglitazone in Lowering A1C but Without Weight Gain in Drug-Naïve Patients With T2D
Inadequate Achievement of ADA Goals Among US Adults With Diabetes
24-Week Sitagliptin Monotherapy Improves Glycemic Control in Patients With Type 2 Diabetes
Sitagliptin Enhances Glycemic Control, beta-Cell Function in Patients With Type 2 Diabetes Not Controlled With Metformin
Vildagliptin + Pioglitazone Improves A1C in Patients Not Controlled With Thiazolidinedione Monotherapy
Change in A1C for Sitagliptin vs Glipizide in Patients Not Controlled With Metformin
Sitagliptin + Metformin Improves 24-Hour Glycemic Control
Vildagliptin vs Rosiglitazone Monotherapy in Type 2 Diabetes: Effects on Body Weight
Vildagliptin vs Rosiglitazone Monotherapy in Type 2 Diabetes: Effects on Lipids
Sitagliptin Improves A1C in Patients With Type 2 Diabetes Not Controlled With Metformin
Sitagliptin Reduces FPG in Patients With Type 2 Diabetes Not Controlled With Metformin
Effect of Sitagliptin on 2-Hour Post-Meal Plasma Glucose in Patients With Type 2 Diabetes Not Controlled With Metformin
Sitagliptin Monotherapy Reduces FPG in Patients With Type 2 Diabetes
Effect of Sitagliptin Monotherapy on A1C in Patients With Type 2 Diabetes
Effect of Sitagliptin Monotherapy on 2-Hour Postprandial Glucose in Patients With Type 2 Diabetes
Changes in A1C Subgroups for Sitagliptin vs Glipizide in Patients Not Controlled With Metformin
Effects of Sitagliptin vs Glipizide on FPG in Patients With Type 2 Diabetes Not Controlled With Metformin
Stroke Risk in Type 2 Diabetes: First 5 Years After Beginning Treatment
Age-Standardized Stroke Rates in Newly Treated Diabetes vs Control
Stroke Risk by Age in Type 2 Diabetes: First 5 Years After Starting Treatment
Cardiovascular Impact of Pioglitazone Therapy: A Meta-analysis
Long-term Risk of Myocardial Infarction With Rosiglitazone: A Meta-analysis
Long-term Risk of Heart Failure With Rosiglitazone: A Meta-analysis
Long-term Risk of Cardiovascular Mortality With Rosiglitazone: A Meta-analysis
Duration of TZD Therapy Prior to Onset of Heart Failure
Dose and Duration of TZD Therapy Prior to Onset of Heart Failure
Frequent Adverse Events in Diabetic Patients Treated With GLP-1 Analogues
Frequent Adverse Events in Diabetic Patients Treated With DPP-4 Inhibitors
Change in A1C for GLP-1 Analogues vs Control in Diabetic Adults
Change in A1C for DPP-4 Inhibitors vs Control in Diabetic Adults
Change in A1C for DPP-4 Inhibitors vs Control in Diabetic Adults (cont)
Effect of Sitagliptin Added to Glimepiride and/or Metformin in Patients With Type 2 Diabetes
ADVANCE: Study Design
ADVANCE: Primary Endpoints
ADVANCE Trial: Intensive Blood Glucose Control in Patients With Type 2 Diabetes
ADVANCE Trial: Combined Major Macrovascular and Microvascular Events
ADVANCE Trial: Risk for Major Macrovascular and Microvascular Events
ACCORD Trial: Intensive Blood Glucose Control in Patients With Type 2 Diabetes
ACCORD Trial: CV Events With Intensive Blood Glucose Control
Once-Weekly vs Twice-Daily Exenatide in Type 2 Diabetes: A1C
Once-Weekly vs Twice-Daily Exenatide in Type 2 Diabetes: Body Weight
Once-Weekly Exenatide LAR vs Twice-Daily Exenatide for Type 2 Diabetes: A1C Categories
Alogliptin and Glyburide Combination Therapy: A1C
Alogliptin Added to Metformin: A1C
Alogliptin Added to Insulin: A1C
Type 2 Diabetes Therapy and Cardiovascular Events: Comparing VADT With Other Trials
ACCORD-MIND: Relationship Between Glycemia Status, Diabetes Duration, and Cognitive Test Scores
Retinopathy Stage, Mean A1C, and Mean Systolic Blood Pressure by Ethnicity
VADT: Primary Endpoint
VADT: Effect of BMI on Rates of Severe Hypoglycemia
Diabetic Retinopathy and Sight-Threatening Conditions: Global Prevalence
Diabetic Retinopathy and Sight-Threatening Conditions: Prevalence and Subgroup Data
DURATION-4: Design
DURATION-4: Mean Change in A1C from Baseline to Week 26
DURATION-4: Additional Outcomes
DURATION-4: Most Common Adverse Events
TINSAL-T2D Trial: Eligibility Criteria and Study Protocol
EUREXA Trial: Change in Body Weight
EUREXA Trial: Hypoglycemia and Adverse Events
EUREXA Trial: Attainment of A1C <7.0% and ≤6.5%
EUREXA Trial: Primary Outcome—Time to Treatment Failure
EUREXA Trial: Design and Enrollment Profile
EUREXA Trial: Design
SEQUEL: Design Extension of CONQUER Study
JUPITER: Lipid and HsCRP Levels
Meta-analysis: Effects of DPP-4 Inhibitors on CV Events Design
Meta-analysis: Effects of DPP-4 Inhibitors on CV Events Results for Primary Endpoint
DURATION-6: Design
DURATION-6: Change in A1C at Week 26
DURATION-6: Secondary Endpoints
DURATION-6: Adverse Events
VADT Post-hoc Analysis: Statin Use and Artery Calcification
Guidelines for Children and Adolescents With Type 2 Diabetes: Physical Activity
Look AHEAD: Continuous, Sustained Type 2 Diabetes Remission
ACCORD: Death from Any Cause
CANTATA-D2: Canagliflozin Noninferior to Sitagliptin for A1C Lowering at 52 Weeks
CANTATA-M: Significant A1C Reductions with Canagliflozin Vs Placebo at 26 Weeks
CANTATA-M: Greater Proportion of Subjects Achieved A1C <7.0% with Canagliflozin vs Placebo at 26 Weeks
ESH/ESC Hypertension Guidelines: Medical History
ESH/ESC Hypertension Guidelines: Treatment of Risk Factors Associated With Hypertension
Look AHEAD: Primary Outcome, Participant Characteristics
Efficacy of Twice-Daily Exenatide Added to Basal Insulin for A1C Reduction: Design
Twice-Daily Exenatide Added to Basal Insulin Vs Placebo : A1C Reduction at 30 Wks
Twice-Daily Exenatide Added to Basal Insulin Vs Placebo: Target A1C Levels at 30 Wks
Twice-Daily Exenatide Added to Basal Insulin Vs Placebo: Body Weight 30 Wks
Twice-Daily Exenatide Added to Basal Insulin Vs Placebo: Hypoglycemia at 30 Wks
Twice-Daily Exenatide Vs Placebo Added to Basal Insulin: Adverse Events
Meta-Analysis: Severe Hypoglycemia Associated with ~2x Risk for CVD
Long-Term Obesity Medications: At Least 5% Weight Loss After 1 Year
AHA/ACC/TOS Obesity Guidelines: Lifestyle Intervention for Weight Maintenance in Adults
Incretins Sulfonylureas Pancreatitis Risk Type 2 Diabetes | NDEI
Incretins Pancreatitis Risk Sulfonylureas Type 2 Diabetes Use Duration | NDEI
Incretins Sulfonylureas Pancreatitis Risk Type 2 Diabetes Gender | NDEI
Incretin Therapies Vs Sulfonylureas Pancreatitis Type 2 Diabetes | NDEI
ACC/AHA Lifestyle Management Guidelines LDL-C | NDEI
ACC/AHA 2013 Lifestyle Management Guideline BP Lowering | NDEI
IDF 2012 Type 2 Diabetes Guidelines Exercise Physical Activity | NDEI
Bariatric Surgery Type 2 Diabetes Remission SOS Study | NDEI
Bariatric Surgery Type 2 Diabetes Complications SOS Study | NDEI
Diabetes Pregnancy Guidelines Preconception CVD Dyslipidemia | NDEI
Metformin Sulfonylureas Cancer Risk Type 2 Diabetes | NDEI
GLP-1 Receptor Agonists A1C Type 2 Diabetes | NDEI
Edinburgh Type 2 Diabetes Hypoglycemia Macrovascular Slides PPT | NDEI
Edinburgh Type 2 Diabetes Hypoglycemia Linked to Inflammation Slides PPT | NDEI
Edinburgh Type 2 Diabetes Inflammation Doesn't Influence Hypoglycemia Slides PPT | NDEI
Diabetes & Aging Study Type 2 Diabetes Remission Linked With Diabetes Duration | NDEI
Changes in Obesity Duration Over Time Among US Adults
ACCORD-MIND Hypoglycemia Age, Intensive Therapy, Diabetes Duration | NDEI
Phentermine + Topiramate for Weight Loss in Type 2 Diabetes | NDEI PPT
A1C Targets for Nonpregnant Individuals
Glycemic Goals for Adults With Type 1 Diabetes
CVD Treatment Statin ADA Type 1 Diabetes Guidelines | NDEI
DURATION-3 & LEAD-5 Post-Hoc Analysis Insulin Type 2 Diabetes PPT | NDEI
A1C Reduction GLP-1 RAs & Insulin in DURATION-3 & LEAD-5 PPT | NDEI
Similar A1C Goal Achievement GLP-1 RA & Glargine DURATION-3 & LEAD-5 | NDEI
Weight Loss With GLP-1 RA & Increase With Glargine in DURATION-3 & LEAD-5 | NDEI
Hypoglycemia With GLP-1 RA & Insulin in DURATION-3 & LEAD-5 PPT | NDEI
Combination GLP-1 RA & Basal Insulin Treatment Type 2 Diabetes | NDEI
AACE 2015 Diabetes Guidelines Glycemic Target A1C PPT | NDEI
ADA EASD Position Statement Individualized Glycemic Targets PPT | NDEI
ELIXA No Cardiovascular Risks Lixisenatide GLP-1 CV Safety | NDEI
TECOS Sitagliptin DPP-4 Inhibitor Pancreatitis Hypoglycemia | NDEI
Hypoglycemia & CVD Risk Type 2 Diabetes AHA ACC Guidelines PPT | NDEI
Saxagliptin Not Associated With Fractures in SAVOR-TIMI 53 Analysis | NDEI
SAVOR-TIMI 53 Saxagliptin Not Associated With Fracture Risk Diabetes | NDEI